To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.
Patients voluntarily participated in the study and signed informed consent with good compliance and follow-up;
Adenocarcinoma of the gastric/gastroesophageal junction confirmed by endoscopic pathology (tumor located in the lesser bend of the stomach other than pylorus or the gastroesophageal junction) (Note: Pathology in other hospitals must be consulted by our hospital);
Patients with cT4N+M0 AJCC stage 8 combined with endoscopic, CT, MRI, or PETCT findings;
Age ≥18 years, ≤75 years, male and female;
a history of surgery for gastric/esophagogastric junction tumors;
Previous history of fistula caused by primary tumor invasion;
Higher risk of gastrointestinal bleeding and perforation;
Poor nutritional status, BMI less than 18.5kg/m2, or PG-SGA score ≥9;